Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-21-PRCRP-IPA: DoD Peer Reviewed Cancer, Impact Award

Closed Closed September 8, 2021 Opportunity W81XWH-21-PRCRP-IPA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.

• Total funding$30.0 million
• Expected awards15
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY21 PRCRP Impact Award supports hypothesis-driven, high-impact research. The Impact Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major near-term impact on at least one of the FY21 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations in underfunded, understudied, and/or lethal militarily relevant cancer or research areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact. The critical components of this award mechanism are: · Impact: The Impact Award is intended to support research that demonstrates the potential to have a major impact in the near term on an area of paramount importance in cancer. The proposed study should demonstrate how the research will transform cancer research toward improved patient outcomes in at least one of the FY21 PRCRP Topic Areas and in at least one of the FY21 PRCRP Overarching Challenges in Section II.A.3 or another critical cancer area. Proposed projects may include translational or clinical research, including clinical trials. The potential impact of the proposed research is expected to be near-term, and it must be significant and go beyond an incremental advance. The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient outcomes. The Impact Award is not intended for basic research. Applicants proposing more basic or long-term impact studies should apply to the FY21 PRCRP Idea Award (W81XWH-21-PRCRP-IA). · Preliminary Data: The Impact Award is intended to support transformative investigations that leapfrog the cancer research field forward by utilizing previous research findings. Applications must include preliminary data to support feasibility of the study. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member of the research team.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.